Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424680 | 0.88 | TGFBR1 (0.52) | TRPV1TGFBR1CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL12424817 | 0.87 | TGFBR1 (0.64) | TRPV1TGFBR1CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2300323 | 0.86 | MPL (0.49) | TRPV1ABCG2MPLMAPK3ACP1 | |
| SCHEMBL12424763 | 0.86 | TRPV1 (0.45) | TRPV1ABCG2MPLMAPK3 | |
| SCHEMBL2302349 | 0.85 | TGFBR1 (0.52) | TRPV1TGFBR1CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2302228 | 0.85 | TGFBR1 (0.64) | TRPV1TGFBR1CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL12090455 | 0.84 | ACP1 (0.56) | TGFBR1CYP1A2CYP3A4CYP2C8ABCG2 | |
| SCHEMBL12425139 | 0.84 | TGFBR1 (0.46) | TRPV1TGFBR1CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2299720 | 0.83 | TRPV1 (0.42) | TRPV1TGFBR1CYP3A4ABCG2MPL | |
| SCHEMBL14227370 | 0.83 | ACP1 (0.51) | TGFBR1CYP1A2CYP3A4CYP2C8ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| CN-103097381-A | 1, 8-naphthyridines as kinase inhibitors | MERCK PATENT GMBH | 2013-05-08 | — | — | CN | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | TRPV1 4168/4885TGFBR1 3742/4885CYP1A2 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.